Skip to main content

Camp4 Therapeutics Corp 8-K, filed Nov 5, 2026

Camp4 Therapeutics Corp (CAMP)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 06, 2026

About this 8-K

Camp4 Therapeutics Corp filed this 8-K on November 5, 2026.

CAMP4 Therapeutics launched the ASCEND Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. It reported $124.5 million in cash and a $29.0 million quarterly net loss. AI summary

Items reported

  • Item 9.01: Financial statements and exhibits